MedTrace Logo

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

NCT01591616 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-08-07

Study results available
· View outcomes & findings →

Summary

To establish Oraqix is safe when used on adolescent volunteers.

Conditions

  • Periodontal Disease

Interventions

DRUG

lidocaine and prilocaine

Appropriate dose of Oraqix based on weight will be given before tooth extraction

Sponsors & Collaborators

  • Dentsply International

    lead INDUSTRY

Principal Investigators

  • Tegwyn Brickhouse, D.D.S PhD · Virginia Commonweath School of Dentistry

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591616 on ClinicalTrials.gov